| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AGT; Ang; Ang I; Ang II; Ang III; Angiotensinogen; ANHU; ANRT; AT-2; AT-II; PAT; Pre angiotensinogen; Serpin A8; SERPINA8;;Angiotensinogen |
| WB Predicted band size | Calculated MW: 52 kDa ; Observed MW: 53-64 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Angiotensinogen |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于Angiotensinogen抗体的虚构参考文献示例(基于常见研究方向模拟)：
1. **文献名称**: "Development of a specific polyclonal antibody for human angiotensinogen detection"
**作者**: Smith J, et al.
**摘要**: 本研究开发了一种针对人源Angiotensinogen的高特异性多克隆抗体，通过免疫兔获得。该抗体在Western blot和免疫组化中表现出高灵敏度，可精准检测肝脏和肾脏组织中的Angiotensinogen表达，为研究其在高血压病理机制中的作用提供了工具。
2. **文献名称**: "Comparative analysis of angiotensinogen immunoassays: Antibody selection impacts quantification in plasma samples"
**作者**: Tanaka K, et al.
**摘要**: 比较了三种不同商业化的Angiotensinogen抗体在ELISA和放射免疫分析法(RIA)中的性能差异，发现抗体表位特异性显著影响血浆样本中Angiotensinogen的检测准确性，提示抗体选择需匹配目标检测形式(如前体蛋白或裂解产物)。
3. **文献名称**: "Angiotensinogen antibody-based transgenic mouse model for hypertension research"
**作者**: Müller R, et al.
**摘要**: 利用针对Angiotensinogen的shRNA抗体构建转基因小鼠模型，特异性抑制肝脏中Angiotensinogen的表达。该模型证实了Angiotensinogen-肾素系统在血压调节中的核心作用，抗体介导的基因沉默为机制研究提供了新方法。
---
注：以上文献为示例性内容，实际引用需通过PubMed/Google Scholar等平台以“angiotensinogen antibody”为关键词检索真实文献。可补充研究方向关键词(如“hypertension”“ELISA”“transgenic”)提高检索精度。
Angiotensinogen (AGT) is a liver-derived glycoprotein and the precursor of angiotensin peptides in the renin-angiotensin system (RAS), a critical regulator of blood pressure, electrolyte balance, and vascular function. Upon cleavage by renin, AGT is converted to angiotensin I, which is further processed into angiotensin II—a potent vasoconstrictor involved in hypertension, cardiovascular disease, and kidney dysfunction. Antibodies targeting AGT are essential tools for studying its expression, localization, and role in RAS-driven pathologies.
AGT antibodies are widely used in immunoassays (e.g., ELISA, Western blot, immunohistochemistry) to quantify protein levels in tissues or biofluids, aiding research on conditions like hypertension, heart failure, and diabetic nephropathy. They also help validate experimental models, such as AGT-knockout mice, and assess therapeutic interventions targeting RAS components. Specificity is critical, as AGT shares structural homology with other serpins. Most commercial AGT antibodies are raised against conserved epitopes in humans or rodents, with monoclonal variants offering higher specificity.
Clinically, AGT antibodies may assist in biomarker studies or diagnostics, though their therapeutic use remains exploratory. Research continues to explore AGT inhibition as a strategy to modulate RAS activity, highlighting the antibody's dual role as a research reagent and potential drug development tool.
×
